Table 1 Immunohistochemical factors and molecular groups
LA (n = 682) | LBH− (N = 166) | LBH+ (N = 47) | H2+ (n = 67) | TN (n = 108) | |
|---|---|---|---|---|---|
Estrogen receptor | |||||
0 % | 67 (100.0) | 108 (100.0) | |||
1–9 % | 14 (2.1) | 4 (2.4 %) | 5 (10.6 %) | ||
≥10 % | 668 (97.9) | 162 (97.6 %) | 42 (89.4 %) | ||
Progesterone receptor | |||||
0 % | 92 (13.5) | 35 (21.1 %) | 16 (34.0 %) | 67 (100.0) | 108 (100.0) |
1–9 % | 45 (6.6) | 22 (13.3 %) | 8 (17.0 %) | ||
≥10 % | 540 (79.2) | 109 (65.7 %) | 22 (46.8 %) | ||
Not specified | 5 (0.7) | 1 (2.1 %) | |||
KI-67 | |||||
<14 % | 611 (89.6) | 13 (27.7 %) | 12 (17.9) | 25 (23.1) | |
14–19 % | 71 (10.4) | 24 (14.5 %) | 12 (25.5 %) | 15 (22.4) | 4 (3.7) |
≥20 % | 142 (85.5 %) | 22 (46.8 %) | 40 (59.7) | 78 (72.2) | |
Not specified | 1 (0.9) | ||||
HER2 | |||||
Negative | 682 (100.0) | 166 (100.0 %) | 108 (100.0) | ||
Positive | 47 (100.0 %) | 67 (100.0) | |||
CK56/EGFR/VIM (Basal phenotype) | |||||
Negative | 615 (90.2) | 146 (88.0 %) | 38 (80.9 %) | 23 (34.3) | 18 (16.7) |
Positive | 48 (7.0) | 15 (9.0 %) | 8 (17.0 %) | 42 (62.7) | 88 (81.5) |
Not specified. | 19 (2.8) | 5 (3.0 %) | 1 (2.1 %) | 2 (3.0) | 2 (1.9) |
ALDH1 | |||||
Negative | 668 (97.9) | 160 (96.4 %) | 43 (91.5 %) | 55 (82.1) | 94 (87.0) |
Positive | 10 (1.5) | 6 (3.6 %) | 4 (8.5 %) | 11 (16.4) | 14 (13.0) |
Not specified | 4 (0.6) | 1 (1.5) | |||
CD24 | |||||
Negative | 452 (66.3) | 86 (51.8 %) | 20 (42.6 %) | 31 (46.3) | 69 (63.9) |
Positive | 225 (33.0) | 80 (48.2 %) | 27 (57.4 %) | 36 (53.7) | 39 (36.1) |
Not specified | 5 (0.7) | ||||
CD44 | |||||
Negative | 300 (44.0) | 85 (51.2 %) | 34 (72.3 %) | 35 (52.2) | 36 (33.3) |
Positive | 364 (53.4) | 80 (48.2 %) | 13 (27.7 %) | 31 (46.3) | 69 (63.9) |
Not specified | 18 (2.6) | 1 (0.6 %) | 1 (1.5) | 3 (2.8) | |
CD24 and CD44 (Claudin phenotype) | |||||
CD24−/CD44+ | 236 (34.6) | 45 (27.1 %) | 4 (8.5 %) | 13 (19.4) | 44 (40.7) |
CD24+/CD44− | 95 (13.9) | 45 (27.1 %) | 18 (38.3 %) | 18 (26.9) | 14 (13.0) |
Other associations | 331 (48.5) | 75 (45.2 %) | 25 (53.2 %) | 35 (52.2) | 47 (43.5) |
Not specified | 20 (2.9) | 1 (0.6 %) | 1 (1.5) | 3 (2.8) | |
E-Cadherine | |||||
Negative | 86 (12.6) | 2 (1.2 %) | 4 (8.5 %) | 3 (4.5) | 7 (6.5) |
Positive | 590 (86.5) | 164 (98.8 %) | 43 (91.5 %) | 63 (94.0) | 99 (91.7) |
Not specified | 6 (0.9) | 1 (1.5) | 2 (1.9) | ||
TRIO phenotype | |||||
Negative | 315 (46.2) | 85 (51.2 %) | 22 (46.8 %) | 31 (46.3) | 59 (54.6) |
Positive | 352 (51.6) | 81 (48.8 %) | 24 (51.1 %) | 36 (53.7) | 48 (44.4) |
Not specified | 15 (2.2) | 1 (2.1 %) | 1 (0.9) | ||
BCL2 phenotype | |||||
Negative | 166 (24.3) | 58 (34.9 %) | 27 (57.4 %) | 61 (91.0) | 95 (88.0) |
Positive | 506 (74.2) | 106 (63.9 %) | 20 (42.6 %) | 6 (9.0) | 11 (10.2) |
Not specified | 10 (1.5) | 2 (1.2 %) | 2 (1.9) | ||